Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 19 December 2025 - 30 December 2025

Pfizer stock slips after hours: what traders are watching ahead of Feb. 3 results

Pfizer stock slips after hours: what traders are watching ahead of Feb. 3 results

NEW YORK, December 29, 2025, 19:33 ET — After-hours Pfizer Inc (NYSE: PFE) shares were down 0.3% at $25 in after-hours trading on Monday, after moving in a tight band during the regular session. The Health Care Select Sector SPDR Fund slipped and large-cap drugmakers traded mixed in late dealings. The move mattered mainly for timing. With just a handful of sessions left in the year and New Year’s around the corner, many investors are adjusting portfolios rather than reacting to fresh company headlines. That leaves Pfizer’s stock trading more on positioning and its most recent guidance than on day-to-day
30 December 2025
···
Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

NEW YORK, December 29, 2025, 2:08 PM ET — Regular session Pfizer shares dipped slightly on Monday, trading down about 0.1% at $25.06 as of 2:08 p.m. ET. The stock has moved between $24.99 and $25.19 in the regular session. The muted move matters because liquidity is thinning into year-end, leaving defensive names like large drugmakers more sensitive to sector headlines and positioning. Reuters reported trading volumes were expected to be light this week, with U.S. markets shut on Thursday for New Year’s Day. Reuters For Pfizer, the backdrop is still its long-dated reset story: investors are weighing whether its
29 December 2025
···
Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

NEW YORK, December 29, 2025, 10:35 ET Live Oak Private Wealth LLC cut its stake in Pfizer (PFE.N) by 92.5% in the third quarter, selling 216,868 shares and ending the period with 17,627 shares, a regulatory filing showed. MarketBeat+2SEC+2 The disclosures matter because quarterly holdings reports are one of the few windows investors get into how money managers were positioned in major stocks heading into the final stretch of the year. The filings can signal shifting conviction in Pfizer, a high-profile name in U.S. healthcare. MarketBeat+2MarketBeat+2 The reports are known as Form 13F filings, which large investment managers submit to
29 December 2025
··
Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

NEW YORK, December 28, 2025, 23:32 ET — Market closed. Pfizer Inc shares edged higher in the last U.S. session, closing Friday up 0.24% at $25.09. The stock traded between $24.92 and $25.11 on the day. Investing.com The modest move leaves Pfizer in the mid-$20s, as investors weigh whether the drugmaker can stabilize revenue after a December reset of expectations for 2026. The next scheduled catalyst is the company’s Feb. 3 quarterly update. Pfizer+1 Pfizer said on Dec. 16 it expects 2026 revenue of $59.5 billion to $62.5 billion and adjusted diluted earnings of $2.80 to $3.00 per share. “Adjusted”
29 December 2025
·
Pfizer Stock (NYSE: PFE) Holds Near $25 as Markets Close for the Weekend: Latest News, Analyst Targets, and What to Watch Monday

Pfizer Stock (NYSE: PFE) Holds Near $25 as Markets Close for the Weekend: Latest News, Analyst Targets, and What to Watch Monday

NEW YORK, Dec. 28, 2025, 2:50 p.m. ET — U.S. stock market closed (Sunday). Pfizer Inc. (NYSE: PFE) heads into the final week of 2025 with its shares hovering in the mid-$20s — a level Wall Street has increasingly framed as a “show-me” zone for investors who want evidence that Pfizer can navigate the post-COVID comedown and looming patent expirations while rebuilding growth through oncology and obesity-focused deals. With U.S. exchanges closed for the weekend, the most actionable information for investors is where Pfizer last finished the regular session, what (limited) fresh weekend reading emerged over the past 24–48 hours,
28 December 2025
··
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

NEW YORK, Dec. 27, 2025, 3:07 p.m. ET — Market closed Pfizer Inc. (NYSE: PFE) is heading into the final trading days of 2025 with its stock still anchored in the mid-$20s, a range that has increasingly defined sentiment around the pharmaceutical giant as Wall Street debates two competing narratives: near-term pressure from fading COVID-era revenues and patent expirations, versus a longer-term rebuild driven by oncology and newer growth categories such as obesity. With U.S. equities closed for the weekend, investors won’t see fresh price discovery until Monday’s opening bell. That matters in a holiday-thinned tape—one where broad indexes have
27 December 2025
···
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer Inc. (NYSE: PFE) heads into Christmas Day with investors digesting a dense run of December headlines: a 2026 outlook that came in below Wall Street expectations, ongoing restructuring and cost-cutting, fresh U.S. drug-pricing initiatives that could reshape the industry’s economics, and multiple pipeline updates spanning oncology, immunology and cardiometabolic disease. U.S. markets are closed on Thursday, Dec. 25, 2025, but Pfizer shares last traded on Wednesday, Dec. 24 at $25.03, after moving between $24.90 and $25.14 intraday, according to the latest available pricing data. Below is a detailed look at the current news, forward guidance, and sell-side forecasts shaping
25 December 2025
···
Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open

Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open

Pfizer, Inc. (NYSE: PFE) ended the trading day higher on Wednesday, December 24, 2025—an early-close session for U.S. equities ahead of Christmas—before holding essentially flat in after-hours trading. The move may look modest on the surface, but it lands at a moment when Pfizer’s stock narrative is unusually “headline-sensitive”: investors are balancing near-term safety scrutiny around a newly approved hemophilia medicine, management’s fresh 2026 outlook, and the longer-running debate over how Pfizer bridges a looming patent cliff with an oncology- and obesity-focused pipeline. PFE stock price after the bell: the closing print and after-hours check-in Here’s the end-of-day snapshot investors
24 December 2025
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer Inc. (NYSE: PFE) stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns. As of Dec. 24, 2025, Pfizer shares were trading around $25 in holiday-thinned markets, leaving the company with a market capitalization of roughly $142 billion and keeping the conversation laser-focused on one question: Can Pfizer rebuild durable growth after the COVID-era revenue boom — and ahead of a looming patent cliff and intensifying U.S.
24 December 2025
···
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

NEW YORK — Pfizer Inc. (NYSE: PFE) is heading into the year-end stretch with investors juggling two competing storylines: near-term pressure from fading COVID-era sales and looming patent expirations, versus a long-term rebuild powered by oncology, internal medicine, and a refreshed pipeline strategy. In holiday-thinned trading on December 24, 2025, Pfizer shares were around $24.93. That “mid‑$20s” level matters because it has become the market’s psychological waiting room: bulls see a discounted global pharma franchise with a large dividend and multiple pipeline shots on goal; bears see a company still searching for its next era-defining growth engine. What’s moving Pfizer
24 December 2025
·
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (NYSE: PFE) ended Tuesday’s session (December 23, 2025) lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi (marstacimab). After-hours snapshot (as of 6:56 p.m. ET): PFE traded around $24.92, up about 0.16% in after-hours action, after closing the regular session at $24.88. Yahoo FinanceDuring Tuesday’s regular session, PFE ranged roughly between $24.84 and $25.34 with volume near 43.7 million shares. Where Pfizer Stock Closed on Dec. 23—and Why the Tape Looked “Holiday Thin” PFE closed down 1.31% at $24.88, snapping a two-day winning streak even as the broader market
24 December 2025
··
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. (NYSE: PFE) stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow adds another variable for investors to price: a safety-related update tied to Pfizer’s hemophilia therapy Hympavzi, landing just as Wall Street digests Pfizer’s newly issued 2026 outlook and the company’s longer road back to growth. What’s moving Pfizer stock on
23 December 2025
···
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer (NYSE: PFE) is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with continued COVID-franchise erosion and an accelerating loss-of-exclusivity cycle. But the longer-term case—outlined in a wave of investor and analyst commentary this month—rests on whether Pfizer can execute in the two areas that matter most to its post-patent-cliff future: oncology and
22 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. (NYSE: PFE) is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure on U.S. drug pricing. As of the most recent close (Friday, Dec. 19), Pfizer stock finished around $25.19, leaving shares squarely in the “mid‑$20s” range where they’ve been pinned for much of the post-pandemic reset. MarketBeat+1 What changed in December—and why investors are still arguing about Pfizer stock—comes down to three big storylines: Below is a comprehensive, up-to-date roundup of
21 December 2025
··
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. (NYSE: PFE) ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term narrative around the long-time pharma bellwether. Reuters+1 Pfizer stock last closed at $25.25 on Friday, Dec. 19, with investors weighing whether the company’s cost-cutting and deal-making can offset the twin headwinds of fading COVID-era revenue and a looming patent cliff. Yahoo Finance+1 Why Pfizer stock is moving: the 2026 forecast reset The biggest driver of this week’s debate is Pfizer’s
21 December 2025
··
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer’s stock is ending 2025 in a familiar place: caught between near-term headwinds (shrinking COVID-era revenue, a growing patent cliff, and U.S. drug-pricing pressure) and a late-decade recovery narrative built around oncology, obesity, and pipeline execution. As of the latest available trade/close data around Dec. 20, Pfizer shares are near $25.19, modestly higher on the most recent session. Investing.com That price level matters because it frames the debate investors are having right now: Is PFE a high-yield “wait-it-out” turnaround, or a value trap until new launches and major clinical wins begin to offset upcoming losses of exclusivity? Below is a
21 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Inc. stock (NYSE: PFE) is ending the week in a familiar place: the mid-$20s. But the story behind that “quiet” price is anything but quiet. Investors are weighing Pfizer’s newly issued 2026 outlook, an evolving U.S. drug-pricing landscape tied to the TrumpRx / most-favored-nation (MFN) framework, and a pipeline-and-deal strategy meant to carry the company through a multi-year patent cliff and the long fade of COVID-era revenue. Reuters+1 Pfizer stock price snapshot: where PFE stands on Dec. 20, 2025 With U.S. markets closed for the weekend, the latest available quote has Pfizer shares around $25.19, after a volatile stretch
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) is ending the week with investors weighing a cautious 2026 outlook against fresh pipeline momentum and a fast-moving U.S. drug-pricing policy backdrop. As of the latest available quote on Friday, Dec. 19, 2025, Pfizer shares traded around $25.37, up about 1.3% on the day, with an intraday range of roughly $24.99 to $25.52 and volume near 43.5 million shares. Below is what’s driving Pfizer stock right now, what management and analysts are forecasting, and what catalysts investors are watching into 2026. Pfizer stock price action on Dec. 19, 2025: why PFE is in focus Pfizer’s share
19 December 2025
··
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) stock was essentially flat on Friday, Dec. 19, 2025, trading around $25.04 in midday trading, after a volatile week that blended policy headlines, a reset of near-term financial expectations, and fresh pipeline updates. For investors, the story around Pfizer stock right now is less about a single headline and more about a three-way tug-of-war: Below is a roundup of the most consequential Pfizer stock news, forecasts, and analysis points investors are digesting as of 19.12.2025. Pfizer stock price today: PFE steadies near $25 as investors weigh policy and guidance As of 14:16 UTC on Dec. 19,
19 December 2025
···
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Inc. (NYSE: PFE) ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing. As of early evening in New York, Pfizer shares were hovering around $25.05 in after-hours trading, after finishing the regular session at $25.04. Google Below is what moved the conversation around Pfizer today, what the latest forecasts imply, and the key items to monitor before the stock market opens Friday (Dec. 19, 2025). Pfizer stock after the bell: where PFE stands heading
19 December 2025
··
1 2 3 4 5 6 7

Stock Market Today

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop